메뉴 건너뛰기




Volumn 3, Issue 2, 2007, Pages 211-220

Rosiglitazone and glimeperide: Review of clinical results supporting a fixed dose combination

Author keywords

Combination; Glimepiride; Rosiglitazone; Sulfonylurea; Thiazolidinediones

Indexed keywords

C REACTIVE PROTEIN; CD40 LIGAND; GELATINASE B; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIMEPIRIDE PLUS ROSIGLITAZONE; GLIPIZIDE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INSULIN GLARGINE; METFORMIN; NITRIC OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; TUMOR NECROSIS FACTOR ALPHA;

EID: 34249848127     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: 10.2147/vhrm.2007.3.2.211     Document Type: Review
Times cited : (6)

References (44)
  • 1
    • 32144448938 scopus 로고    scopus 로고
    • Standards of Medical Care in Diabetes
    • American Diabetes Association
    • American Diabetes Association. 2006. Standards of Medical Care in Diabetes. Diabetes Care, 29:S4-42.
    • (2006) Diabetes Care , vol.29
  • 2
    • 3042849235 scopus 로고    scopus 로고
    • Comparison of uptitration of gliclazide with the addition of rosiglitazone to gliclazide in patients with type 2 diabetes inadequately controlled on half-maximal doses of a sulphonylurea
    • Baksi A, James RE, Zhou B, et al. 2004. Comparison of uptitration of gliclazide with the addition of rosiglitazone to gliclazide in patients with type 2 diabetes inadequately controlled on half-maximal doses of a sulphonylurea. Acta Diabetol, 41:63-9.
    • (2004) Acta Diabetol , vol.41 , pp. 63-69
    • Baksi, A.1    James, R.E.2    Zhou, B.3
  • 3
    • 0035094340 scopus 로고    scopus 로고
    • The pleiotropic functions of peroxisome proliferator-activated receptor γ
    • Debril MB, Renaud JP, Fajas L, et al. 2002. The pleiotropic functions of peroxisome proliferator-activated receptor γ. J Mol Med, 79:30-47.
    • (2002) J Mol Med , vol.79 , pp. 30-47
    • Debril, M.B.1    Renaud, J.P.2    Fajas, L.3
  • 4
    • 2942550710 scopus 로고    scopus 로고
    • Metabolic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and metabolic syndrome treated with glimepiride: A twelve month, multicenter, randomized, controlled, parallel group trial
    • Derosa G, Cicero AF, Gaddi AV, et al. 2004. Metabolic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and metabolic syndrome treated with glimepiride: a twelve month, multicenter, randomized, controlled, parallel group trial. Clin Ther, 26:744-54.
    • (2004) Clin Ther , vol.26 , pp. 744-754
    • Derosa, G.1    Cicero, A.F.2    Gaddi, A.V.3
  • 5
    • 20444439480 scopus 로고    scopus 로고
    • A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome
    • Derosa G, Cicero AF, Gaddi AV, et al. 2005a. A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome. Diabetes Res Clin Pract. 69:5-13.
    • (2005) Diabetes Res Clin Pract , vol.69 , pp. 5-13
    • Derosa, G.1    Cicero, A.F.2    Gaddi, A.V.3
  • 6
    • 27744539460 scopus 로고    scopus 로고
    • Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: A 12 month, double-blind, randomized clinical trial
    • Derosa G, Cicero AF, Gaddi AV, et al. 2005b. Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12 month, double-blind, randomized clinical trial. Clin Ther, 27:1383-91.
    • (2005) Clin Ther , vol.27 , pp. 1383-1391
    • Derosa, G.1    Cicero, A.F.2    Gaddi, A.V.3
  • 7
    • 33645979004 scopus 로고    scopus 로고
    • Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: A randomized, double-blind, clinical trial
    • Derosa G, Gaddi AV, Piccinni MN, et al. 2006. Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double-blind, clinical trial. Diabetes Obes Metab, 8:197-205.
    • (2006) Diabetes Obes Metab , vol.8 , pp. 197-205
    • Derosa, G.1    Gaddi, A.V.2    Piccinni, M.N.3
  • 8
    • 21244443895 scopus 로고    scopus 로고
    • Sulfonylurea agents exhibit peroxisome proliferator-activated receptor gamma agonistic activity
    • Fukuen S, Iwaki M, Yasui A, et al. 2005. Sulfonylurea agents exhibit peroxisome proliferator-activated receptor gamma agonistic activity. J Biol Chem, 280:23653-9.
    • (2005) J Biol Chem , vol.280 , pp. 23653-23659
    • Fukuen, S.1    Iwaki, M.2    Yasui, A.3
  • 9
    • 34249857906 scopus 로고    scopus 로고
    • GlaxoSmithKline. 2006. URL: http://US.gsk.com/product/assets/us_fixed combination of glimepiride and rosiglitazone.pdf
    • (2006) URL: http
    • GlaxoSmithKline1
  • 10
    • 0037031267 scopus 로고    scopus 로고
    • Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus
    • Haffner SM, Greenberg AS, Weston WM, et al. 2002. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation, 106:679-84.
    • (2002) Circulation , vol.106 , pp. 679-684
    • Haffner, S.M.1    Greenberg, A.S.2    Weston, W.M.3
  • 11
    • 0036895990 scopus 로고    scopus 로고
    • Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes
    • Hallsten JK, Virtanen KA, Lonnqvist F, et al. 2002. Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes. Diabetes, 51:3479-85.
    • (2002) Diabetes , vol.51 , pp. 3479-3485
    • Hallsten, J.K.1    Virtanen, K.A.2    Lonnqvist, F.3
  • 12
    • 28444484176 scopus 로고    scopus 로고
    • Efficacy and Safety of Rosiglitazone in Combination with Glimepiride
    • Hamann A, Matthaei S, Mauersberger H, et al. 2003. Efficacy and Safety of Rosiglitazone in Combination with Glimepiride. Diabetes Metab, 29(Suppl 2):2288.
    • (2003) Diabetes Metab , vol.29 , Issue.SUPPL. 2 , pp. 2288
    • Hamann, A.1    Matthaei, S.2    Mauersberger, H.3
  • 13
    • 17644427988 scopus 로고    scopus 로고
    • Reduction in use of healthcare services with combination sulfonylurea and rosiglitazone: Findings ftom the Rosiglitazone Early vs SULfonylurea Titration (RESULT) study
    • Herman WH, Dirani RG, Horblyuk R, et al. 2005. Reduction in use of healthcare services with combination sulfonylurea and rosiglitazone: findings ftom the Rosiglitazone Early vs SULfonylurea Titration (RESULT) study. Am J Manag Care, 11:273-8.
    • (2005) Am J Manag Care , vol.11 , pp. 273-278
    • Herman, W.H.1    Dirani, R.G.2    Horblyuk, R.3
  • 14
    • 33845405222 scopus 로고    scopus 로고
    • Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
    • Kahn SE, Haffner SM, Heise MA, et al. 2006 Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med, 355:2427-43.
    • (2006) N Engl J Med , vol.355 , pp. 2427-2443
    • Kahn, S.E.1    Haffner, S.M.2    Heise, M.A.3
  • 15
    • 0942300619 scopus 로고    scopus 로고
    • Combination therapy with rosiglitazone and glibenclamide compared with upward titration of glibenclamide alone in patients wit type 2 diabetes mellitus
    • Kerenyi Z, Samer H, James R, et al. 2004. Combination therapy with rosiglitazone and glibenclamide compared with upward titration of glibenclamide alone in patients wit type 2 diabetes mellitus. Diabetes Res Clin Pract, 63:213-23.
    • (2004) Diabetes Res Clin Pract , vol.63 , pp. 213-223
    • Kerenyi, Z.1    Samer, H.2    James, R.3
  • 16
    • 0034713444 scopus 로고    scopus 로고
    • Roles of PPARs in health and disease
    • Kersten S, Desvergne B, Wahli W. 2000. Roles of PPARs in health and disease. Nature, 405:421-4.
    • (2000) Nature , vol.405 , pp. 421-424
    • Kersten, S.1    Desvergne, B.2    Wahli, W.3
  • 17
    • 0031955215 scopus 로고    scopus 로고
    • Glimiperide. A Review of its use in the management of type 2 diabetes mellitus
    • Langtry HD, Balfour JA. 1998. Glimiperide. A Review of its use in the management of type 2 diabetes mellitus. Drugs, 55:563-84.
    • (1998) Drugs , vol.55 , pp. 563-584
    • Langtry, H.D.1    Balfour, J.A.2
  • 18
    • 0037324289 scopus 로고    scopus 로고
    • Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease
    • Marx N, Froehlich J, Siam L, et al. 2003a. Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. Arterioscier Thromb Vasc Biol, 23:283-8.
    • (2003) Arterioscier Thromb Vasc Biol , vol.23 , pp. 283-288
    • Marx, N.1    Froehlich, J.2    Siam, L.3
  • 19
    • 0037461106 scopus 로고    scopus 로고
    • Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease
    • Marx N, Imhof A, Froehlich J, et al. 2003b. Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease. Circulation, 107:1954-7.
    • (2003) Circulation , vol.107 , pp. 1954-1957
    • Marx, N.1    Imhof, A.2    Froehlich, J.3
  • 20
    • 0035012433 scopus 로고    scopus 로고
    • Clinical review of glimepiride
    • McCall AL. 2001. Clinical review of glimepiride. Expert Opin Pharmacother, 2:699-713.
    • (2001) Expert Opin Pharmacother , vol.2 , pp. 699-713
    • McCall, A.L.1
  • 21
    • 11844271546 scopus 로고    scopus 로고
    • Results of a randomized, double-blind, placebo-controlled study administering glimepiride to patients with type 2 diabetes mellitus inadequately controlled with rosiglitazone monotherapy
    • McCluskey D, Touger MS, Melis R, et al. 2004. Results of a randomized, double-blind, placebo-controlled study administering glimepiride to patients with type 2 diabetes mellitus inadequately controlled with rosiglitazone monotherapy. Clin Ther, 26:1793-90.
    • (2004) Clin Ther , vol.26 , pp. 1793-1790
    • McCluskey, D.1    Touger, M.S.2    Melis, R.3
  • 22
    • 2942655390 scopus 로고    scopus 로고
    • Evidence for a potent antiinflammatory effect of rosiglitazone
    • Mohanty P, Aljada A, Ghanim H, et al. 2004. Evidence for a potent antiinflammatory effect of rosiglitazone. J Clin Endocrinol Metab, 89:2728-35.
    • (2004) J Clin Endocrinol Metab , vol.89 , pp. 2728-2735
    • Mohanty, P.1    Aljada, A.2    Ghanim, H.3
  • 23
    • 2542424151 scopus 로고    scopus 로고
    • Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes
    • Natali A, Baldeweg S, Toschi E, et al. 2004. Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes. Diabetes Care, 27:1349-57.
    • (2004) Diabetes Care , vol.27 , pp. 1349-1357
    • Natali, A.1    Baldeweg, S.2    Toschi, E.3
  • 24
    • 13444279939 scopus 로고    scopus 로고
    • Addition of rosiglitazone to glimepiride and metformin combination therapy in type 2 diabetes
    • Orbay E, Sargin M, Sargin H, et al. 2004. Addition of rosiglitazone to glimepiride and metformin combination therapy in type 2 diabetes. Endocr J, 51:521-7.
    • (2004) Endocr J , vol.51 , pp. 521-527
    • Orbay, E.1    Sargin, M.2    Sargin, H.3
  • 25
    • 4744355176 scopus 로고    scopus 로고
    • Intact and total proinsulin: New aspects fbr diagnosis and treatment of type 2 diabetes
    • Pfützner A, Kann P, Pfützner AH, et al. 2004. Intact and total proinsulin: new aspects fbr diagnosis and treatment of type 2 diabetes. Clin Lab, 50:567-73.
    • (2004) Clin Lab , vol.50 , pp. 567-573
    • Pfützner, A.1    Kann, P.2    Pfützner, A.H.3
  • 26
    • 28444495456 scopus 로고    scopus 로고
    • Impact of rosiglitazone on β-cell function, insulin resistance and adiponektin concentrations - Results from a double blind oral combination study with glimepiride
    • Pfützner A, Schöndorf T, Seidel D, et al. 2006a. Impact of rosiglitazone on β-cell function, insulin resistance and adiponektin concentrations - Results from a double blind oral combination study with glimepiride. Metabolism 55:20-5.
    • (2006) Metabolism , vol.55 , pp. 20-25
    • Pfützner, A.1    Schöndorf, T.2    Seidel, D.3
  • 27
    • 34249858012 scopus 로고    scopus 로고
    • Mesenchymal stem cell differentiation into adipocytes is equally induced by insulin and proinsulin in vitro
    • Pfützner A, Pansky A, Maiworm A, et al. 2006b. Mesenchymal stem cell differentiation into adipocytes is equally induced by insulin and proinsulin in vitro. Diabetologia, 49(Suppl 1):P-707.
    • (2006) Diabetologia , vol.49 , Issue.SUPPL. 1
    • Pfützner, A.1    Pansky, A.2    Maiworm, A.3
  • 29
    • 28444482714 scopus 로고    scopus 로고
    • Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: Results from a 30-week, randomized, double-blind, placebo-controlled, parallel-group study
    • Roberts VL, Stewart J, Issa M, et al. 2005. Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results from a 30-week, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther, 27:1535-47.
    • (2005) Clin Ther , vol.27 , pp. 1535-1547
    • Roberts, V.L.1    Stewart, J.2    Issa, M.3
  • 30
    • 33645988220 scopus 로고    scopus 로고
    • Effect of early addition of rosiglitazone to sulphonylurea therapy in older patients with type 2 diabetes (>60 years): The Rosiglitazone Early vs SULfonylurea Titration (RESULT) study
    • Rosenstock J, Goldstein BJ, Vinik AI, et al. 2005. Effect of early addition of rosiglitazone to sulphonylurea therapy in older patients with type 2 diabetes (>60 years): the Rosiglitazone Early vs SULfonylurea Titration (RESULT) study. Diabetes Obes Metab, 8:49-57.
    • (2005) Diabetes Obes Metab , vol.8 , pp. 49-57
    • Rosenstock, J.1    Goldstein, B.J.2    Vinik, A.I.3
  • 31
    • 33745000699 scopus 로고    scopus 로고
    • Triple therapy in type 2 diabetes: Insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients
    • Rosenstock J, Sugimoto D, Strange P, et al. 2006a. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Care, 29:554-9.
    • (2006) Diabetes Care , vol.29 , pp. 554-559
    • Rosenstock, J.1    Sugimoto, D.2    Strange, P.3
  • 32
    • 34249852784 scopus 로고    scopus 로고
    • Rosiglitazone added early to glimepiride provides superior glycaemic control than uptitration of glimepiride alone in type 2 diabetes (T2DM)
    • Rosenstock J, Ferreira-Cornwell C, Weston WM, et al. 2006b. Rosiglitazone added early to glimepiride provides superior glycaemic control than uptitration of glimepiride alone in type 2 diabetes (T2DM). Diabetes, 55(Suppl,1):P-549.
    • (2006) Diabetes , vol.55 , Issue.SUPPL.and1
    • Rosenstock, J.1    Ferreira-Cornwell, C.2    Weston, W.M.3
  • 33
    • 0026651718 scopus 로고
    • Stimulation by proinsulin of expression of plasminogen activator inhibitor type-I in endothelial cells
    • Schneider DJ, Nordt TK, Sobel BE. 1992. Stimulation by proinsulin of expression of plasminogen activator inhibitor type-I in endothelial cells. Diabetes, 41:890-5.
    • (1992) Diabetes , vol.41 , pp. 890-895
    • Schneider, D.J.1    Nordt, T.K.2    Sobel, B.E.3
  • 34
    • 0034681773 scopus 로고    scopus 로고
    • Thiazolidinediones: An update
    • Schoonjans K, Auwerx J. 2000. Thiazolidinediones: an update. Lancet, 355:1008-10.
    • (2000) Lancet , vol.355 , pp. 1008-1010
    • Schoonjans, K.1    Auwerx, J.2
  • 35
    • 0041366838 scopus 로고    scopus 로고
    • Treatment with rosiglitazone reduces hyperinsulinemia and improves arterial elasticity in patients with type 2 diabetes mellitus
    • Shargorodsky M, Wainstein J, Gavish D, et al. 2002. Treatment with rosiglitazone reduces hyperinsulinemia and improves arterial elasticity in patients with type 2 diabetes mellitus. Am J Hypertens, 16:617-22.
    • (2002) Am J Hypertens , vol.16 , pp. 617-622
    • Shargorodsky, M.1    Wainstein, J.2    Gavish, D.3
  • 36
    • 3242745192 scopus 로고    scopus 로고
    • Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes
    • Tiikkainen M, Hakkinen AM, Korsheninnikova E, et al. 2004. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes, 53:2169-76.
    • (2004) Diabetes , vol.53 , pp. 2169-2176
    • Tiikkainen, M.1    Hakkinen, A.M.2    Korsheninnikova, E.3
  • 37
    • 26244444497 scopus 로고    scopus 로고
    • Glimepiride induces nitric oxide production in human coronary artery endothelial cells via a PI3-kinase-Akt dependent pathway
    • Ueba H, Kuroki M, Hashimoto S, et al. 2005. Glimepiride induces nitric oxide production in human coronary artery endothelial cells via a PI3-kinase-Akt dependent pathway. Atherosclerosis, 183:35-9.
    • (2005) Atherosclerosis , vol.183 , pp. 35-39
    • Ueba, H.1    Kuroki, M.2    Hashimoto, S.3
  • 38
    • 0036965689 scopus 로고    scopus 로고
    • An international study of the effects of rosiglitazone plus sulphonylurea in patients with type 2 diabetes
    • Vongthavaravat V, Wajchenberg BL, Waitman JN, et al. 2002. An international study of the effects of rosiglitazone plus sulphonylurea in patients with type 2 diabetes. Curr Med Res Opin, 18:456-61.
    • (2002) Curr Med Res Opin , vol.18 , pp. 456-461
    • Vongthavaravat, V.1    Wajchenberg, B.L.2    Waitman, J.N.3
  • 39
    • 0036343675 scopus 로고    scopus 로고
    • Rosiglitazone: A review of its use in the management of type 2 diabetes mellitus
    • Wagstaff AJ, Goa KL. 2002. Rosiglitazone: a review of its use in the management of type 2 diabetes mellitus. Drugs, 62:1805-37.
    • (2002) Drugs , vol.62 , pp. 1805-1837
    • Wagstaff, A.J.1    Goa, K.L.2
  • 40
    • 23744434472 scopus 로고    scopus 로고
    • Rosiglitazone/Metformin
    • Wellington K. 2005. Rosiglitazone/Metformin. Drugs, 65:1581-92.
    • (2005) Drugs , vol.65 , pp. 1581-1592
    • Wellington, K.1
  • 41
    • 0033975057 scopus 로고    scopus 로고
    • Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients
    • Wolffenbüttel BH, Gomis R, Squatrito S, et al. 2000. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients. Diab Med, 17:40-7.
    • (2000) Diab Med , vol.17 , pp. 40-47
    • Wolffenbüttel, B.H.1    Gomis, R.2    Squatrito, S.3
  • 42
    • 0038509992 scopus 로고    scopus 로고
    • Efffect of addition of low-dose rosiglitazone to sulphonylurea therapy on glycaemic control in type 2 diabetic patients
    • Yang J, Di F, He R, et al. 2003. Efffect of addition of low-dose rosiglitazone to sulphonylurea therapy on glycaemic control in type 2 diabetic patients. Chin Med J (Engl), 116:785-7.
    • (2003) Chin Med J (Engl) , vol.116 , pp. 785-787
    • Yang, J.1    Di, F.2    He, R.3
  • 43
    • 0242501570 scopus 로고    scopus 로고
    • Addition of rosiglitazone to existing sulfonylurea treatment in chinese patients with type 2 diabetes and exposure to hepatitis B or C
    • Zhu XX, Pan CY, Li GW, et al. 2003. Addition of rosiglitazone to existing sulfonylurea treatment in chinese patients with type 2 diabetes and exposure to hepatitis B or C. Diabetes Technol Ther, 5:33-42.
    • (2003) Diabetes Technol Ther , vol.5 , pp. 33-42
    • Zhu, X.X.1    Pan, C.Y.2    Li, G.W.3
  • 44
    • 0035856920 scopus 로고    scopus 로고
    • Global and societal implications of the diabetes epidemic
    • Zimmet P, Alberti KG, Shaw J. 2001. Global and societal implications of the diabetes epidemic. Nature, 407:782-7.
    • (2001) Nature , vol.407 , pp. 782-787
    • Zimmet, P.1    Alberti, K.G.2    Shaw, J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.